Study Of Hepatitis B Virus Infection In Patients With Multiple Myeloma

Objective:The aim of this study is to research the influence factors of patients with the Multiple Myeloma (Multiple Myeloma, MM) infected with hepatitis B virus (HBV), and analysis of the factors affecting the prognosis of patients with Multiple Myeloma.Methods-.In this study we collect 56 multiple myeloma patients diagnosed in June 2010 to June 2014,collect their cases and follow-up as case group, follow-up to December 2015. Select 56 physical examination as a control during this period, the age, sex of them were matched.We compare the HBV infection rate between case group and control group. Further research were done to analysis correlation between general information and HBV infection of MM patients.Prognostic factors for case group were study by COX regression analysis.Results:(l)The hepatitis B surface antigen (HBsAg) positivity rate was significantly higher in the MM group(p=0.015).(2)There was no significant difference between the two gourps in gender,age,immune classification, D-S stage, ISS stage,and fatty liver.The rate of HCV and HEV infection also did not differ between the two groups;The incidence of cirrhosis was significantly higher in HBsAg+patients(27.3% vs.4.4% in HBsAg- patients;p=0.047);Hepatic damage was much more common in HBsAg+ patients than in HBsAg- patients both prior to (36.4% vs.8.9%;p=0.040) and during chemotherapy for MM (63.6% vs.28.9%;p=0.041).(3)ISS stage, HBsAg, the use of bortezomib and thalidomide and autologous stem cell transplant were significant factors for overall survival in Kaplan-Meier analysis by log-rank test.(4) In the Cox regression analysis, ISS stage (p=0.028), HBsAg+ (p=0.044) and the use of thalidomide (p=0.011) showed a significant effect on the OS of these patients.Conclusions:Patients with MM relative to the general population are more likely to be infected with hepatitis b virus. The rate of positive HBsAg of MM patients combined liver cirrhosis is higher, the HBsAg positive rate of MM patients who were hepatic dysfunction before therapy is higher, HBsAg positive patients are more likely to appear hepatic dysfunction during therapy. ISS stage, HBsAg positive, the use of thalidomide were the independent factors affecting the prognosis.